Portfolio of human colorectal adenocarcinomas

Reference number 5129

Sectors: Medical research, Pharmaceuticals

Industries: Biotechnology

A portfolio of human colorectal adenocarcenoma cell lines including primary cell lines isolated from patients (of various Duke’s stages and histological grades) in addition to cloned cells lines genetically modified to highly express alpha integrin domains.

Technology overview

Primary

Six cell lines from primary human colorectal adenocarcinomas were established from surgical specimens without the use of ‘feeder’ cells, ‘conditioned’ medium or passage of cells in nude mice. The six cell lines exhibit considerable variation in morphology, CEA secretion and tumourigenicity in nude mice. At least two of the lines retain some of the differentiated characteristics of colorectal epithelium. HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium.

Clonal

HRA-19a1.1 is a clone derived from HRA-19. The HRA-19a1.1 cell line was transfected with alpha integrin domain coding plasmids to create cell lines highly expressing alpha2 or alpha2 and alpha 1 integrin. In experiments, cell lines expressing alpha2 showed a significantly increased endrocrine and mucous cell lineage commitment relative to the parent cell line.

Benefits

  • Cell lines are invaluable tools for biomedical research.
  • Cancer cell lines are the foundation of cancer biology and the quest for drug treatments.
  • Adenocarcinoma is a cancer of the epithelium (including colon) and originates in glandular tissue, such as skin surface layer and glands.

Purchasing these cell lines

This portfolio of human colorectal adenocarcenoma cell lines is available from Public Health England ECCAC

ECACC Logo

Purchase directly from ECCAC

Contact

Dr Emily Allen-Benton

Industry Partnerships and Commercialisation Officer, Medicine

Emily is an IPC Officer within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which included the Faculty of Medicine Quicktech portfolio, comprising mouse models and other research tools. Emily holds a PhD in Chemistry focussed […]

Contact Emily

e.allen-benton@imperial.ac.uk

Related technologies

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...